<DOC>
	<DOC>NCT00371254</DOC>
	<brief_summary>This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.</brief_summary>
	<brief_title>A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>females, 18 or older recurrent or progressive locally advanced, or 'triple negative' metastatic breast cancer paraffinembedded tissue block must be available measurable disease prior chemotherapy with an anthracycline, a taxane, or both (neoadjuvant, adjuvant, or metastatic setting) 0, 1 or 2 chemotherapies in the metastatic setting adequate organ function Metastatic disease confined to bone only Symptomatic CNS metastasis Concurrent medical condition which may increase the risk of toxicity Unable to take oral medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Recurrent, locally-advanced, or 'triple negative' metastatic breast cancer</keyword>
</DOC>